SPECIAL

Immunotherapy as first-line treatment for metastatic NSCLC

T. Feys

Targeted therapies for non-metastatic NSCLC

T. Feys

New therapeutic targets in patients with advanced NSCLC

A. Dekker, T. Feys

The changing first-line treatment landscape for patients with ALK-positive NSCLC

T. Feys

Overcoming crizotinib resistance in ROS1-positive NSCLC

T. Feys

Dual EGFR-VEGF strategy in EGFR-mutant NSCLC

T. Feys

Real-world treatment practices for EGFR-mutant NSCLC patients

A. Dekker, T. Feys